查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1866587

双特异性抗体疗法：全球市场份额和排名、总收入和需求预测（2025-2031年）

Bi-Specific Antibodies Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球双特异性抗体疗法市场预计在 2024 年达到 41.65 亿美元，预计到 2031 年将达到 180.56 亿美元，2025 年至 2031 年的复合年增长率为 23.4%。

双特异性抗体（BsAb）或双特异性单株抗体（BsMAb）是由两种不同抗体的片段组成的人工合成蛋白。由于含有两个不同的抗原结合域，双特异性抗体可以辨识并结合两种不同的抗原，或结合同一抗原上的两个不同表位。

双特异性抗体疗法市场的成长受多种因素驱动，包括临床需求的增加、技术进步、投资动能以及监管支持。其中一个关键驱动因素是全球癌症发生率的上升，尤其是骨髓恶性肿瘤和难治性固态肿瘤，这催生了对更精准、更有效的免疫疗法的强劲需求。双特异性抗体能够同时靶向两种不同的抗原，从而增强特异性和免疫激活，并已成为肿瘤治疗领域极具前景的下一代疗法。

生物技术和抗体工程的进步显着加速了双特异性抗体平台的发展。过去，结构复杂性、稳定性差和生产产量低等挑战限制了其发展。然而，蛋白质设计、表现系统和药物传递技术的突破催生了临床可行的抗体形式，例如双特异性T细胞衔接器（BiTEs）、交叉单株抗体（CrossMabs）和DVD-Igs。这些创新提高了抗体的生产性能、稳定性和疗效，为更广泛的临床研发奠定了基础。

同时，投资者对生物製药领域的兴趣和资金筹措不断增加，推动了双特异性抗体研发的扩张。在创业投资和策略合作的支持下，成熟的製药公司和生技新兴企业都在增加对该领域的投资。美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构在审查新型生物製药时也展现出弹性，有助于缩短研发週期，并加速双特异性疗法的市场进入。

与传统治疗方法相比，标靶性强、个人化的疗法疗效较佳，患者对此越来越接受。双特异性抗体通常具有脱靶毒性低、免疫介导的癌细胞杀伤作用强等优点，进一步促进了其临床应用。

摘要，双特异性抗体疗法市场受到未被满足的需求、日趋成熟的技术、强有力的资金支持和有利的法规环境的驱动，这些因素共同造就了一个快速增长且具有高潜力的治疗领域。

主要企业包括罗氏、安进、赛诺菲、辉瑞和强生。全球前五名生产商占据了超过95%的市场。北美是最大的市场，约占65%的份额，其次是欧洲和中国，各占30%以上的份额。依产品类型划分，IgG类抗体是最大的细分市场，占85%以上的市占率。按应用领域划分，血友病是最大的应用领域，其次是肿瘤治疗和其他治疗。

本报告旨在按地区/国家、类型和应用对全球双特异性抗体疗法市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

本报告以销售收入为指标，对双特异性抗体疗法市场规模、估算和预测进行了呈现，以2024年为基准年，并涵盖了2020年至2031年的历史数据和预测数据。报告结合定量和定性分析，旨在帮助读者制定双特异性抗体疗法的业务和成长策略，评估市场竞争，分析公司在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Roche
  • Amgen
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • AbbVie
  • Lindis Biotech
  • MacroGenics, Inc
  • Genmab
  • Alphamab Co. Ltd
  • Akeso, Inc.

按类型分類的细分市场

  • 基于片段的抗体
  • 基于IgG的抗体

应用领域

  • 癌症
  • 血友病
  • 其他非癌症疾病

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Bi-Specific Antibodies Therapy was estimated to be worth US$ 4165 million in 2024 and is forecast to a readjusted size of US$ 18056 million by 2031 with a CAGR of 23.4% during the forecast period 2025-2031.

A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.

The growth of the bispecific antibody therapy market is driven by a combination of rising clinical demand, technological advancements, investment momentum, and regulatory support. One of the primary drivers is the increasing global incidence of cancer-particularly hematological malignancies and treatment-resistant solid tumors-which has created a strong demand for more precise and effective immunotherapies. Bispecific antibodies, with their ability to simultaneously target two different antigens, offer enhanced specificity and immune activation, positioning them as a promising next-generation therapeutic approach in oncology.

Advancements in biotechnology and antibody engineering have significantly accelerated the development of bispecific platforms. Historically, challenges such as structural complexity, poor stability, and low manufacturing yield limited their progress. However, breakthroughs in protein design, expression systems, and drug delivery technologies have enabled the emergence of clinically viable formats such as BiTEs (bispecific T-cell engagers), CrossMabs, and DVD-Igs. These innovations have improved manufacturability, stability, and efficacy, paving the way for a broader clinical pipeline.

In parallel, growing investor interest and funding in the biopharmaceutical sector have fueled the expansion of bispecific antibody R\&D. Both established pharmaceutical companies and biotech startups are increasingly investing in this field, supported by active venture capital and strategic partnerships. Regulatory bodies like the FDA and EMA are also showing flexibility in reviewing novel biologics, facilitating faster development timelines and market access for bispecific therapies.

On the patient side, there is increasing acceptance of targeted, personalized treatments that offer superior outcomes compared to traditional therapies. Bispecific antibodies often demonstrate reduced off-target toxicity and enhanced immune-mediated tumor cell killing, further driving clinical adoption.

In summary, the bispecific antibody therapy market is being propelled by unmet clinical needs, technological maturation, strong financial backing, and a favorable regulatory environment-factors that together are shaping a rapidly growing and high-potential therapeutic space.

Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%. North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.

This report aims to provide a comprehensive presentation of the global market for Bi-Specific Antibodies Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Bi-Specific Antibodies Therapy by region & country, by Type, and by Application.

The Bi-Specific Antibodies Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific Antibodies Therapy.

Market Segmentation

By Company

  • Roche
  • Amgen
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • AbbVie
  • Lindis Biotech
  • MacroGenics, Inc
  • Genmab
  • Alphamab Co. Ltd
  • Akeso, Inc.

Segment by Type

  • Fragment-Based Antibodies
  • IgG-Based Antibodies

Segment by Application

  • Cancer
  • Haemophilia
  • Other Non-Cancer Diseases

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Bi-Specific Antibodies Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Bi-Specific Antibodies Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Bi-Specific Antibodies Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Bi-Specific Antibodies Therapy Product Introduction
  • 1.2 Global Bi-Specific Antibodies Therapy Market Size Forecast (2020-2031)
  • 1.3 Bi-Specific Antibodies Therapy Market Trends & Drivers
    • 1.3.1 Bi-Specific Antibodies Therapy Industry Trends
    • 1.3.2 Bi-Specific Antibodies Therapy Market Drivers & Opportunity
    • 1.3.3 Bi-Specific Antibodies Therapy Market Challenges
    • 1.3.4 Bi-Specific Antibodies Therapy Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Bi-Specific Antibodies Therapy Players Revenue Ranking (2024)
  • 2.2 Global Bi-Specific Antibodies Therapy Revenue by Company (2020-2025)
  • 2.3 Key Companies Bi-Specific Antibodies Therapy Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Bi-Specific Antibodies Therapy Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Bi-Specific Antibodies Therapy
  • 2.6 Bi-Specific Antibodies Therapy Market Competitive Analysis
    • 2.6.1 Bi-Specific Antibodies Therapy Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Bi-Specific Antibodies Therapy Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific Antibodies Therapy as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Fragment-Based Antibodies
    • 3.1.2 IgG-Based Antibodies
  • 3.2 Global Bi-Specific Antibodies Therapy Sales Value by Type
    • 3.2.1 Global Bi-Specific Antibodies Therapy Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Bi-Specific Antibodies Therapy Sales Value, by Type (2020-2031)
    • 3.2.3 Global Bi-Specific Antibodies Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Cancer
    • 4.1.2 Haemophilia
    • 4.1.3 Other Non-Cancer Diseases
  • 4.2 Global Bi-Specific Antibodies Therapy Sales Value by Application
    • 4.2.1 Global Bi-Specific Antibodies Therapy Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Bi-Specific Antibodies Therapy Sales Value, by Application (2020-2031)
    • 4.2.3 Global Bi-Specific Antibodies Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Bi-Specific Antibodies Therapy Sales Value by Region
    • 5.1.1 Global Bi-Specific Antibodies Therapy Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Bi-Specific Antibodies Therapy Sales Value by Region (2020-2025)
    • 5.1.3 Global Bi-Specific Antibodies Therapy Sales Value by Region (2026-2031)
    • 5.1.4 Global Bi-Specific Antibodies Therapy Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.2.2 North America Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.3.2 Europe Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Bi-Specific Antibodies Therapy Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.5.2 South America Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.3.2 United States Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.4.2 Europe Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.5.2 China Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.6.2 Japan Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.7.2 South Korea Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Bi-Specific Antibodies Therapy Sales Value, 2020-2031
    • 6.9.2 India Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Bi-Specific Antibodies Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Roche
    • 7.1.1 Roche Profile
    • 7.1.2 Roche Main Business
    • 7.1.3 Roche Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.1.4 Roche Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Roche Recent Developments
  • 7.2 Amgen
    • 7.2.1 Amgen Profile
    • 7.2.2 Amgen Main Business
    • 7.2.3 Amgen Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.2.4 Amgen Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Amgen Recent Developments
  • 7.3 Sanofi
    • 7.3.1 Sanofi Profile
    • 7.3.2 Sanofi Main Business
    • 7.3.3 Sanofi Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.3.4 Sanofi Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Sanofi Recent Developments
  • 7.4 Pfizer
    • 7.4.1 Pfizer Profile
    • 7.4.2 Pfizer Main Business
    • 7.4.3 Pfizer Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.4.4 Pfizer Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Pfizer Recent Developments
  • 7.5 Johnson & Johnson
    • 7.5.1 Johnson & Johnson Profile
    • 7.5.2 Johnson & Johnson Main Business
    • 7.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.5.4 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Johnson & Johnson Recent Developments
  • 7.6 AstraZeneca
    • 7.6.1 AstraZeneca Profile
    • 7.6.2 AstraZeneca Main Business
    • 7.6.3 AstraZeneca Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.6.4 AstraZeneca Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.6.5 AstraZeneca Recent Developments
  • 7.7 AbbVie
    • 7.7.1 AbbVie Profile
    • 7.7.2 AbbVie Main Business
    • 7.7.3 AbbVie Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.7.4 AbbVie Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.7.5 AbbVie Recent Developments
  • 7.8 Lindis Biotech
    • 7.8.1 Lindis Biotech Profile
    • 7.8.2 Lindis Biotech Main Business
    • 7.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.8.4 Lindis Biotech Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Lindis Biotech Recent Developments
  • 7.9 MacroGenics, Inc
    • 7.9.1 MacroGenics, Inc Profile
    • 7.9.2 MacroGenics, Inc Main Business
    • 7.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.9.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.9.5 MacroGenics, Inc Recent Developments
  • 7.10 Genmab
    • 7.10.1 Genmab Profile
    • 7.10.2 Genmab Main Business
    • 7.10.3 Genmab Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.10.4 Genmab Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Genmab Recent Developments
  • 7.11 Alphamab Co. Ltd
    • 7.11.1 Alphamab Co. Ltd Profile
    • 7.11.2 Alphamab Co. Ltd Main Business
    • 7.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.11.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Alphamab Co. Ltd Recent Developments
  • 7.12 Akeso, Inc.
    • 7.12.1 Akeso, Inc. Profile
    • 7.12.2 Akeso, Inc. Main Business
    • 7.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Products, Services and Solutions
    • 7.12.4 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Akeso, Inc. Recent Developments

8 Industry Chain Analysis

  • 8.1 Bi-Specific Antibodies Therapy Industrial Chain
  • 8.2 Bi-Specific Antibodies Therapy Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Bi-Specific Antibodies Therapy Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Bi-Specific Antibodies Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Bi-Specific Antibodies Therapy Market Trends
  • Table 2. Bi-Specific Antibodies Therapy Market Drivers & Opportunity
  • Table 3. Bi-Specific Antibodies Therapy Market Challenges
  • Table 4. Bi-Specific Antibodies Therapy Market Restraints
  • Table 5. Global Bi-Specific Antibodies Therapy Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Bi-Specific Antibodies Therapy Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Bi-Specific Antibodies Therapy Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Bi-Specific Antibodies Therapy Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Bi-Specific Antibodies Therapy
  • Table 10. Global Bi-Specific Antibodies Therapy Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific Antibodies Therapy as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Bi-Specific Antibodies Therapy Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Bi-Specific Antibodies Therapy Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Bi-Specific Antibodies Therapy Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Bi-Specific Antibodies Therapy Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Bi-Specific Antibodies Therapy Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Bi-Specific Antibodies Therapy Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Bi-Specific Antibodies Therapy Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Bi-Specific Antibodies Therapy Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Bi-Specific Antibodies Therapy Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Bi-Specific Antibodies Therapy Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Bi-Specific Antibodies Therapy Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Bi-Specific Antibodies Therapy Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Bi-Specific Antibodies Therapy Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Bi-Specific Antibodies Therapy Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Bi-Specific Antibodies Therapy Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Roche Basic Information List
  • Table 32. Roche Description and Business Overview
  • Table 33. Roche Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Roche (2020-2025)
  • Table 35. Roche Recent Developments
  • Table 36. Amgen Basic Information List
  • Table 37. Amgen Description and Business Overview
  • Table 38. Amgen Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Amgen (2020-2025)
  • Table 40. Amgen Recent Developments
  • Table 41. Sanofi Basic Information List
  • Table 42. Sanofi Description and Business Overview
  • Table 43. Sanofi Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Sanofi (2020-2025)
  • Table 45. Sanofi Recent Developments
  • Table 46. Pfizer Basic Information List
  • Table 47. Pfizer Description and Business Overview
  • Table 48. Pfizer Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Pfizer (2020-2025)
  • Table 50. Pfizer Recent Developments
  • Table 51. Johnson & Johnson Basic Information List
  • Table 52. Johnson & Johnson Description and Business Overview
  • Table 53. Johnson & Johnson Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Johnson & Johnson (2020-2025)
  • Table 55. Johnson & Johnson Recent Developments
  • Table 56. AstraZeneca Basic Information List
  • Table 57. AstraZeneca Description and Business Overview
  • Table 58. AstraZeneca Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of AstraZeneca (2020-2025)
  • Table 60. AstraZeneca Recent Developments
  • Table 61. AbbVie Basic Information List
  • Table 62. AbbVie Description and Business Overview
  • Table 63. AbbVie Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of AbbVie (2020-2025)
  • Table 65. AbbVie Recent Developments
  • Table 66. Lindis Biotech Basic Information List
  • Table 67. Lindis Biotech Description and Business Overview
  • Table 68. Lindis Biotech Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Lindis Biotech (2020-2025)
  • Table 70. Lindis Biotech Recent Developments
  • Table 71. MacroGenics, Inc Basic Information List
  • Table 72. MacroGenics, Inc Description and Business Overview
  • Table 73. MacroGenics, Inc Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of MacroGenics, Inc (2020-2025)
  • Table 75. MacroGenics, Inc Recent Developments
  • Table 76. Genmab Basic Information List
  • Table 77. Genmab Description and Business Overview
  • Table 78. Genmab Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Genmab (2020-2025)
  • Table 80. Genmab Recent Developments
  • Table 81. Alphamab Co. Ltd Basic Information List
  • Table 82. Alphamab Co. Ltd Description and Business Overview
  • Table 83. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Alphamab Co. Ltd (2020-2025)
  • Table 85. Alphamab Co. Ltd Recent Developments
  • Table 86. Akeso, Inc. Basic Information List
  • Table 87. Akeso, Inc. Description and Business Overview
  • Table 88. Akeso, Inc. Bi-Specific Antibodies Therapy Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Bi-Specific Antibodies Therapy Business of Akeso, Inc. (2020-2025)
  • Table 90. Akeso, Inc. Recent Developments
  • Table 91. Key Raw Materials Lists
  • Table 92. Raw Materials Key Suppliers Lists
  • Table 93. Bi-Specific Antibodies Therapy Downstream Customers
  • Table 94. Bi-Specific Antibodies Therapy Distributors List
  • Table 95. Research Programs/Design for This Report
  • Table 96. Key Data Information from Secondary Sources
  • Table 97. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Bi-Specific Antibodies Therapy Product Picture
  • Figure 2. Global Bi-Specific Antibodies Therapy Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Bi-Specific Antibodies Therapy Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Bi-Specific Antibodies Therapy Report Years Considered
  • Figure 5. Global Bi-Specific Antibodies Therapy Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Bi-Specific Antibodies Therapy Revenue in 2024
  • Figure 7. Bi-Specific Antibodies Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Fragment-Based Antibodies Picture
  • Figure 9. IgG-Based Antibodies Picture
  • Figure 10. Global Bi-Specific Antibodies Therapy Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Bi-Specific Antibodies Therapy Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Cancer
  • Figure 13. Product Picture of Haemophilia
  • Figure 14. Product Picture of Other Non-Cancer Diseases
  • Figure 15. Global Bi-Specific Antibodies Therapy Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global Bi-Specific Antibodies Therapy Sales Value Market Share by Application, 2024 & 2031
  • Figure 17. North America Bi-Specific Antibodies Therapy Sales Value (2020-2031) & (US$ Million)
  • Figure 18. North America Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 19. Europe Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 20. Europe Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Asia Pacific Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Asia Pacific Bi-Specific Antibodies Therapy Sales Value by Region (%), 2024 VS 2031
  • Figure 23. South America Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. South America Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 25. Middle East & Africa Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. Middle East & Africa Bi-Specific Antibodies Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Key Countries/Regions Bi-Specific Antibodies Therapy Sales Value (%), (2020-2031)
  • Figure 28. United States Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. United States Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 30. United States Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 31. Europe Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Europe Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 33. Europe Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 34. China Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. China Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 36. China Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 37. Japan Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. Japan Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 39. Japan Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 40. South Korea Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. South Korea Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 42. South Korea Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 43. Southeast Asia Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. Southeast Asia Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 45. Southeast Asia Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 46. India Bi-Specific Antibodies Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. India Bi-Specific Antibodies Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 48. India Bi-Specific Antibodies Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 49. Bi-Specific Antibodies Therapy Industrial Chain
  • Figure 50. Bi-Specific Antibodies Therapy Manufacturing Cost Structure
  • Figure 51. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 52. Bottom-up and Top-down Approaches for This Report
  • Figure 53. Data Triangulation
  • Figure 54. Key Executives Interviewed